Evidence map›Paper›PMID 25986698›Full record

ArticleNeuropharmacology2015

Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function.

Stephen D Mague, Russell G Port, Michael E McMullen, Greg C Carlson, Jill R Turner

Abstract read
In one paragraph

Article in Neuropharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Translational Research in Nicotine Addiction.Cold Spring Harbor perspectives in medicine · 2021
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Stephen D MagueDepartment of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Russell G PortDepartment of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Michael E McMullenDepartment of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Greg C CarlsonDepartment of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Jill R TurnerDepartment of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC 29036, USA. Electronic address: jiturner@sccp.sc.edu.
University of Pennsylvania · USUniversity of South Carolina · US

Funding

FELLOWSHIP IN IV TREATMENT RESEARCHT32DA007241 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI O'BRIEN, CHARLES P · 1990 to 2006
$1.5M
Pharmacogenomic Analysis of Nicotine DependenceR00DA032681 · NIDA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI TURNER, JILL R. · 2014 to 2016
$741k
Pharmacogenomic Analysis of Nicotine DependenceK99DA032681 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI TURNER, JILL R. · 2013 to 2013
$133k
NIDA NIH HHS K99 DA032681NIDA NIH HHS R00 DA032681NIDA NIH HHS R00-DA-032681NIDA NIH HHS T32 DA007241NIDA NIH HHS T32-DA-007241-15NIMHD NIH HHS L60 MD006479
6 · The paper itself

Abstract

A single nucleotide polymorphism (SNP) in the human μ-opioid receptor gene (OPRM1 A118G) has been widely studied for its association in a variety of drug addiction and pain sensitivity phenotypes; however, the extent of these adaptations and the mechanisms underlying these associations remain elusive. To clarify the functional mechanisms linking the OPRM1 A118G SNP to altered phenotypes, we used a mouse model possessing the equivalent nucleotide/amino acid substitution in the Oprm1 gene. In order to investigate the impact of this SNP on circuit function, we used voltage-sensitive dye imaging in hippocampal slices and in vivo electroencephalogram recordings of the hippocampus following MOPR activation. As the hippocampus contains excitatory pyramidal cells whose activity is highly regulated by a dense network of inhibitory neurons, it serves as an ideal structure to evaluate how putative receptor function abnormalities may influence circuit activity. We found that MOPR activation increased excitatory responses in wild-type animals, an effect that was significantly reduced in animals possessing the Oprm1 SNP. Furthermore, in order to assess the in vivo effects of this SNP during MOPR activation, EEG recordings of hippocampal activity following morphine administration corroborated a loss-of-function phenotype. In conclusion, as these mice have been shown to have similar MOPR expression in the hippocampus between genotypes, these data suggest that the MOPR A118G SNP results in a loss of receptor function.

Indexed as

Polymorphism, Single NucleotideAnalgesics, OpioidAnimalsElectrocorticographyEnkephalin, Ala(2)-MePhe(4)-Gly(5)-FemaleGenotypeHippocampusMaleMice, Inbred C57BLMice, TransgenicModels, AnimalReceptors, Opioid, muTissue Culture TechniquesVoltage-Sensitive Dye ImagingAnalgesics, OpioidEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Oprm protein, mouseReceptors, Opioid, muA112GA118GGenotypeHippocampusMiceMu-opioid receptorN40DOPRM1SexSingle nucleotide polymorphism

Identifiers

PMID25986698
PMCPMC4536923
OpenAlexW892373514

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.